Propeller Health and GSK have announced that their December 2015 agreement for development of a sensor for use with the Ellipta dry powder inhaler has been expanded, and R&D activities related to the use of the Propeller platform with GSK products for asthma and COPD will continue. The Propeller clip-on sensor for the Ellipta DPI received CE mark approval and 510(k) clearance in 2016.
According to the announcement, the purpose of the extended collaboration is “to prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s Ellipta inhaler.”
Propeller Health CEO David Van Sickle commented, “We are excited to be working closely with GSK to make the sensor for the Ellipa inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US. Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”
GSK Senior VP and Head, Global Respiratory Franchise, Eric Dube,said, “Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition. We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”
Read the Propeller Health and GSK press release.
